Stipple Bio
Stub active Updated Apr 7, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Stipple Bio is a Cambridge, Massachusetts-based biotechnology company focused on precision oncology 1. Founded in 2022 by Dr. Aaron Ring (Fred Hutch) and Dr. Aashish Manglik (UCSF), the company emerged from stealth in April 2026 12. Stipple Bio’s proprietary Pointillist Platform identifies tumor-specific cell surface epitopes to develop targeted cancer therapies with high therapeutic indices while minimizing off-tumor toxicity 1. The lead candidate, STP-100, is a novel antibody-drug conjugate expected to enter early-stage clinical trials in early 2027 12. The Series A proceeds will fund operations into 2029 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-06 | Series A | $100M | RA Capital, a16z Bio+Health, Nextech Invest | Emerson Collective Investments, GV, LoLa Capital Partners, GordonMD Global Investments 12 |
What Investors Say
No verified investor quotes available at this time.
What Founders Say
No verified founder quotes available at this time.
Sources
-
BioSpace, “Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing,” April 6, 2026. https://www.biospace.com/press-releases/stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a-precision-oncology-pipeline-that-leverages-its-pointillist-platform↩↩↩↩↩↩
-
GlobeNewsWire, “Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A,” April 6, 2026. https://www.globenewswire.com/news-release/2026/04/06/3268331/0/en/Stipple-Bio-Emerges-From-Stealth-with-Oversubscribed-100-Million-Series-A-Financing-to-Advance-STP-100-into-Early-Clinical-Studies-and-Advance-a-Precision-Oncology-Pipeline-that-Le.html↩↩↩